Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1) pri...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Boddu, Prajwal, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Ravandi, Farhad, Verstovsek, Srdan, Jabbour, Elias, Borthakur, Gautam, Konopleva, Marina, Bhalla, Kapil N., Daver, Naval, DiNardo, Courtney D., Benton, Christopher B., Takahashi, Koichi, Estrov, Zeev, Pierce, Sherry R., Andreeff, Michael, Cortes, Jorge E., Kadia, Tapan M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2017
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727976/
https://ncbi.nlm.nih.gov/pubmed/29296774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017008227
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky